* Sees "broadly stable" 2017 earnings
* Revenue growth in nearly all divisions but diabetes
* Pleased with Dupixent uptake
* Profits in line with forecast (Adds details)
PARIS, July 31 (Reuters) - French drugmaker Sanofi raised its 2017 outlook on the back of strong growth at its consumer healthcare, vaccines and Genzyme arms in the second quarter, and said it was encouraged by the uptake of a key new eczema drug in the United States.
The company said it was now expecting "broadly stable" earnings per share (EPS) this year compared to a previous forecast of stable to slightly lower EPS.
In March, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biologic drug for atopic dermatitis - also referred to as eczema - Dupixent, that will sell for a list price of $37,000 for a year of treatment.
Chief Executive Olivier Brandicourt told journalists that sales of Dupixent in its first full quarter on the market had reached 26 million euros ($30.54 million).
He said over 13,000 patients had been prescribed with the medication, which also received a positive recommendation from a European Medicines Agency panel earlier this month.
Despite high selling prices and fierce competition, biologics are seen as a potential answer to a vast array of diseases. In June, Sanofi said it would invest further in this field.
Dupixent is also considered a key drug for Sanofi and Regeneron, as it is also being developed for severe asthma.
Sanofi said second-quarter net income was down 0.5 percent at constant exchange rates to 1.7 billion euros ($2 billion) - in line with analysts' forecasts. Total sales rose 5.5 percent to 8.66 billion euros.
While nearly all of Sanofi's units recorded double-digit revenue growth in the quarter, sales at the group's embattled but core diabetes division were down 15 percent due to persistent pricing pressure in the United States, where prescriptions of cheaper copies of the group's treatments are picking up.
Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.7 billion euros and net sales of 8.7 billion.
The geographical mix of sales showed strong momentum in emerging markets and Europe but falling revenues in the U.S.
($1 = 0.8514 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)